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The evidence for conversion from brand name to generic equivalent cyclosporine is conﬂicting. Cyclosporine is a narrow
therapeutic-range drug for which small variations in exposure may have severe clinical consequences for transplant patients.
There is currently a lack of comparative outcome data relating to the pharmacokinetics of the reference formulation, Neoral,
and generic formulations in transplant recipients. A major common concern is the potential inability to attain similar trough
levels, an issue that can be easily corrected by ongoing therapeutic drug monitoring to ensure that the new steady state falls within
an intended target range. Prospective clinical studies investigating the eﬃcacy and safety of generic formulations in both de novo
and long-term transplant patients are also awaited. Until further evidence is available on the conversion of transplant patients to
or between generic formulations of cyclosporine, any transfer to a diﬀerent cyclosporine formulation should be undertaken with
close supervision. The best available information to date, however, does not support the frequently held but unsubstantiated belief
thatgenericpreparationsofimmunosuppressivedrugsarenotaseﬀectiveasbrandnamesorthatconversionfrombrandtogeneric
is associated with signiﬁcant danger. This paper attempts to initiate a discussion of these issues.
1.Background
The discovery of cyclosporine was a landmark in the history
of solid organ transplantation. It was initially isolated from
the fungus Tolypocladium inﬂatum from a soil sample
obtained by Sandoz scientists at Hardangervidda, Norway
in 1970 [1]. Cyclosporine is a cyclic nonribosomal peptide
of 11 amino acids and contains a single D-amino acid,
which is rarely encountered in nature. The drug exhibits
very poor solubility in water and is lipophilic. As a conse-
quence, suspension and emulsion forms of the drug have
been developed for oral administration and for injection.
Cyclosporine was originally brought to market by Sandoz,
now Novartis, under the brand name Sandimmune in 1983.
It had variable bioavailability among patients with diarrhea,
biliary diversion, diabetic gastroparesis, or malabsorption
secondary to its high dependence on bile solubility [2].
This was addressed by the introduction of a microemulsion
formulation, Neoral [3, 4] (Novartis), in July 1995. Several
other similar cyclosporine formulations have subsequently
beenintroducedinthemarket,andatimeline issummarized
in Table 1.
Neoral, as the branded product, has been the favored
choice of physicians for many years despite facing com-
petition from the available generics. The approval process
for generics was simpliﬁed after introduction of legislation
in 1984 (commonly known as the Waxman-Hatch amend-
ments). The process, also known as “Abbreviated New Drug
Applications” (ANDA) has helped to increase availability
of generic—or AB-rated—equivalents. The current FDA
standard of AB rating indicates that bioequivalence has been
studied and demonstrated and is the standard mandated
criteria for generic formulations of all prescription drugs.
Generics are tested against Brand in healthy young
volunteers by giving a single dose of the reference for-
mulation and the generic formulation that is being tested.
BioequivalencestudiesareperformedusingAUC(areaunder
the time-concentration curve) and Cmax (maximum plasma
concentration) to demonstrate that the generic has similar
pharmacokinetics as the brand formulation. AUC serves as2 Journal of Transplantation
Table 1: Cyclosporine development timeline.
Date Signiﬁcant event
November
1983
Sandimmune (cyclosporine) oral solution
approval
March 1990 Sandimmune (cyclosporine) capsule approval
July 1995 Neoral capsules and solution approval (brand
cyclosporine modiﬁed)
October 1998 SangStat’s SangCya (generic cyclosporine
modiﬁed) approval
January 2000 Cyclosporine modiﬁed capsules (Sandoz)
approval
May 2000 Cyclosporine modiﬁed capsules (Gengraf,
Abbott)
December
2000 SangCya withdrawal
December
2000
Cyclosporine modiﬁed capsules (Pliva)
approval
December
2001
Cyclosporine modiﬁed solution (Pliva)
approval
May 2002 Cyclosporine capsules (generic Sandimmune,
Apotex) approval
September
2004
Cyclosporine solution (generic Sandimmune,
Morton Grove) approval
January 2005 Cyclosporine modiﬁed solution (Novex)
approval
March 2005 Cyclosporine modiﬁed capsules and solution
(Ivax) approval
a surrogate for the extent of absorption whereas the Cmax
and the time of its occurrence (tmax) together characterize
the rate of absorption [5–7]. It is concluded that two
pharmaceutical agents are not diﬀerent from one another if
the 90% conﬁdence interval of the ratio of a log-transformed
exposure measure (AUC and/or Cmax) falls within the
range 80–125%. Unless otherwise indicated by a speciﬁc
guidance statement, the traditional bioequivalence limit of
80 to 125 percent is the same for nonnarrow therapeutic
range drugs and for narrow therapeutic range drugs. The
80–125% bioequivalence acceptance range translates into
ad i ﬀerence of −20 to +25% in the rate and extent of
absorption between two drug products for a single dose
exposure. Standard bioequivalence criteria do not require
the generic formulation to be evaluated in target patient
populations, over repeated exposure, in unhealthy people,
or by administration intravenously. In addition, generics are
not tested against other generics.
Some physicians and patients have raised concerns over
generic versions of critical drugs by claiming a diﬀerence in
quality and therapeutic eﬃcacycompared to the brand name
drug [7–9]. The arguments given are as follows.
(1) The FDA acceptance limits for generics (80–125%) is
too broad as there is a potential diﬀerence of as much
as 45%.
(2) Generic drugs are tested only in healthy volunteers
and may act diﬀerently in the target disease popula-
tion, resulting in uncontrolled clinical risks.
Every transplant physician encounters situations where a
choice between brand versus generic formulation arises for
ﬁnancial or insurance reasons. For narrow therapeutic index
drugs, this decision becomes more critical. The FDA deﬁnes
these products as “those containing drug substances that are
subject to therapeutic drug concentration or pharmacody-
namicmonitoring,and/orwhereproductlabelingindicatesa
narrow therapeutic range designation” [10]. As cyclosporine
is a critical dose/narrow therapeutic index drug, a change in
drug level has the potential to either cause rejection or result
inrenaltoxicitydependingonloworhighlevels,respectively.
Many pharmacies in the United States are increasingly
substituting micro emulsion forms of cyclosporine, either by
mandate or by choice. State regulations vary on the require-
ment of pharmacists to notify primary care providers of
generic cyclosporine substitution, and subsequent additional
therapeutic drug monitoring to verify consistency in drug
exposure is frequently not undertaken. This, in turn, often
leads to doubts in the physician’s as well as the patient’s
mind, and ultimately leads to specifying “DAW” (dispense
as written) on the hand-written prescription.
One of the reasons given for the prospering generic
marketishealthcaredollarsavings.Ithasbeenestimatedthat
use of generics instead of brand name drugs in the year 2000
inAmericaalonewouldhavesaved$8.8billion,equivalentto
11% of total drug expenditure [11]. Another explanation for
the prospering generic market is improved compliance with
less expensive medications, for obvious reasons. However, in
regards to cyclosporine generics, there have been concerns
about the savings from their use in transplant patients. The
argument given is that upfront savings are oﬀset by the cost
incurred by rejection of grafts, frequent monitoring of drug
levels, or even the increased dosage requirement for the drug
[12].
The purpose of this discussion is to review evidence
for and against equivalence between brand and AB-rated
equivalent cyclosporine, and thereby assist the transplant
community in making knowledgeable decisions.
2. SupportingData
There is scarcity of studies comparing Neoral with generic
cyclosporine. In our literature search we came across
fewer than half a dozen published articles addressing this
important issue. Several studies have been reported from
European countries claiming equivalence of generic and
brand cyclosporine [13, 14] while one from a US center has
suggested more frequent graft rejection on generic Gengraf
[15]. The existing package insert for Neoral includes data
relatedtolimitedcomparisonswithgenericSandimmunefor
transplant, rheumatoid arthritis, and psoriasis patients. In
general,Neoral hadincreasedbioavailability whencompared
to Sandimmune in small absorption studies. The mean
cyclosporine area under the curve (AUC) and peak blood
cyclosporine concentration (Cmax)w e r eb o t hh i g h e rf o r
Neoral, but dose-normalized trough concentrations were
similarforbothformulations.Thepercentageofdosepresent
as major metabolites was also similar in both preparations.Journal of Transplantation 3
The main backbone of generic formulations—bioe-
quivalence—has been questioned in some studies. The
inability of standard testing to conﬁrm bioequivalence in a
transplant population was demonstrated in the case of the
SangCyA formulation of CsA. SangCya had a Class II recall
byFDA,issuedonproductsthathavealowchanceofcausing
major injuries or death, but where there is still the possibility
of serious adverse events with irreversible consequences. It
was voluntarily withdrawn from the market in 2000 after
initial approval in 1998 following successful bioequivalence
studiesinhealthyvolunteers.Itwasfoundthatbioavailability
for SangCya was signiﬁcantly diﬀerent in comparison to
Neoral when consumed with apple juice [16]. This ﬁnding
highlightedthefactthatknownandunknownvariables,even
something as innocuous as coadministration of apple juice,
may create potential confusion.
In the solid organ transplant setting, additional lim-
itations in regards to bioequivalence testing have given
rise to concerns [17]. Cyclosporine absorption may diﬀer
between healthy volunteers and transplant recipients [6];
indeed, absorption variability in transplant recipients has
been documented to be related to time after transplantation
and the type of organ graft [18, 19]. In addition, patient
c h a r a c t e r i s t i c ss u c ha sa g e[ 20, 21], ethnicity [22, 23], or
comorbid disease [24, 25]m a ya ﬀect cyclosporine absorp-
tion.
Isolatedreportshavebeenpublishedthatotherimmuno-
suppressivemedicationabsorption,includingsirolimus,may
be aﬀected by generic versus brand cyclosporine formula-
tions [26]. Intestinal drug-drug interactions are a general
problemintransplantationandcanoccurwhenfoods,herbal
drugs, and other drug formulations are taken at the same
time as the immunosuppressant. This issue is obviously not
unique to either brand or generic drugs.
Currently, there is a paucity of data relating to the
eﬃcacy and safety of transferring transplant patients from
reference Neoral formulations to a generic formulation or,
indeed, from one generic form of cyclosporine to another.
There are few studies evaluating pharmacokinetics or clinical
outcomesbetweenthecyclosporinemicroemulsionreference
drug (Neoral) and AB-rated bioequivalents (namely, Gen-
graf). The following two studies have assessed the eﬀect of
transferring stable renal transplant patients from the Neoral
to a generic formulation (Gengraf) of cyclosporine.
Roza et al. [27] switched 50 stable renal allograft
recipients in a multicenter, US-based study, from Neoral
t oG e n g r a fa n dt h e nb a c kt oN e o r a lo v e r3 5d a y so na
dose-for-dose basis. This trial found no signiﬁcant diﬀerence
in the mean pharmacokinetic measurements during the
three periods of the study, and there was no need for dose
adjustment in any patient. The authors concluded that the
pharmacokinetics of Gengraf were equivalent to those of
Neoral. No statistically signiﬁcant diﬀerences in Cmax, AUC0
→ 12hr, Cmin, and T max between Neoral at day 14 and
Gengraf at day 28 were observed. However, only mean values
of pharmacokinetic parameters were provided (Cmax,t r o u g h
blood concentration (C0), AUC, and time to maximum
blood concentration (tmax)), without any individual data or
ranges.
A second study by Carnahan and Cooper [28]i n v o l v e d
41 stable kidney transplant patients in an open-label
clinical trial. The trial was conducted primarily to assess
diﬀerences in steady-state cyclosporine concentration and
serum creatinine after conversion from Neoral to Gengraf.
Secondary goals were to evaluate changes in cyclosporine
dosing regimen, Cyclosporine toxicity, graft rejection, hos-
pital/emergency room admission, and changes with medi-
cations which could interact with cyclosporine. The authors
reported no untoward incidents after an average of 18 weeks.
The FDA acknowledges the limitations of bioequivalence
studies and recognizes the need for increased assurance of
the interchangeability for drug products containing narrow
therapeutic index (NTI) drugs. FDA suggests additional
testing and/or controls to ensure the quality of drug product
containing immunosuppressant [10].
Concerns were raised in a study by Qazi et al. [29]w h e r e
6-month postrenal transplant patients with stable graft
function were randomized to either remain on Neoral (n =
9) or switch to Gengraf (n = 73). Serum creatinine and
cyclosporine troughs were measured at baseline and 2 weeks
after the switch. Of the studied patients, 13 (18%) required
a dose change after transfer to Gengraf. The mean CsA
trough level in all patients converted to Gengraf rose from
180.5±8.4ng/mLto195.0±9.8ng/mL(P<0.05),whichwas
statistically (but not necessarily clinically) signiﬁcant. Inter-
estingly,themeanbaselineCsAlevelwas234±96ng/mL,rose
to289±102ng/mLafterconversion,andfellbackto239±151
after decreasing the dosage. The mean serum creatinine did
not rise signiﬁcantly. No dose changes were required among
the patients who remained on Neoral. In summary, the Qazi
studyof82stablerenaltransplantrecipientsatleast6months
after transplant revealed that nearly 20% of patients who
switched to a generic CsA preparation that was considered
bioequivalent required a dose adjustment to return to the
preconversion cyclosporine trough level. The potential for
adverse eﬀects resulting from such conversions (especially in
patientswhoareseenonlyonceinseveralmonths)andwhen
the patient or the transplant care providers are unaware of
the switch is of considerable concern, but true outcome data
are still not available.
In 2006, Hibberd et al. [30] reported a study from Aus-
tralia comparing Cysporin (generic) versus Neoral kinetics.
The pharmacokinetic proﬁle of Cysporin and Neoral were
found to be diﬀerent: for Cysporin the extent of absorption
was lower and the rate of absorption was slower than
that for Neoral. The authors felt that a trial in transplant
recipients(nothealthyvolunteers)isneededtodeterminethe
pharmacokinetics and bioequivalence of a generic immuno-
suppressant,particularlyacriticalconcentration-timeproﬁle
drug such as cyclosporine A.
In 1999, the National Kidney Foundation published
a White Paper consensus [31] document to suggest rec-
ommendations for the safe and eﬀective use of generic
immunosuppressantsbasedontheexpertopinionofamulti-
disciplinary group of participants and their review of the
literature. In summary, recommendations for improving the
FDA approval standards for generic immunosuppressants
included the following.4 Journal of Transplantation
(1) Deﬁning critical-dose drug characteristics and
inclusion of immunosuppressive agents such as
cyclosporine and tacrolimus in the list of critical-
dose drugs.
(2) Need for replicable pharmacokinetic studies of criti-
caldosedrugsaspartoftheapprovalprocessforboth
the innovator drugs as well as subsequent generics.
(3) Bioequivalence studies in subpopulations of trans-
plant patients (e.g., pediatric, African-American, or
diabetic patients).
Further recommendations were made pertaining to safe
and eﬀective use of generic immunosuppressant agents,
including the following.
(1) Patient education and involvement in decision mak-
ing before any switch from brand to generic and also
from one generic to another.
(2) Consistency in state regulations for pharmacist to
notify the patient as well as physician prior to any
substitution of an immunosuppressive medication.
(3) Careful evaluation of bioequivalence data for drugs
by physicians, so that appropriate prescribing deci-
sions can be made related to generic substitution.
(4) Consideration for appropriate drug monitoring
techniques (including blood levels) if patients are
switched from one formulation to another (e.g.,
brand to generic, generic to generic).
(5) The importance of documenting and reporting
adverse events with innovator and generic drugs.
(6) Patient education to identify drug formulations and
to alert the physician if a drug is substituted.
The American Society of Transplantation [32] published a
similar report in 2003 on the use of generic immunosup-
pressants in the transplant settings. Recommendations are
summarized as follows.
(1) Need for consistency in use of selected immunosup-
pression formulation, timing of drug administration,
and blood level monitoring.
(2) Need for “pill and container” uniqueness among
generic alternatives
(3) Need for physicians and patients to be notiﬁed by
pharmacistsifthereisanyswitchindispensedbrands
(4) Need for patients to inform physician if any switch
has taken place so that appropriate drug monitoring
can be undertaken.
(5) Incorporating bioequivalence studies in at-risk pa-
tient populations into generic drug approval process.
MostparticipantsintheAmericanSocietyofTransplantation
forum [32]s u p p o r t e dde novo usage of generic cyclosporine
in low-risk patients or even a switch from brand to generic as
long as the patient and care providers are clearly informed
about the switch, so that when indicated additional tests
could be performed to ensure desired drug levels. Because
of insuﬃcient bioequivalence data in the African American
and pediatric population, generic substitution was not
recommended in these groups.
Both AST and NKF recommendations for practice and
policy seem rational and safe approaches while more deﬁni-
tive data are accumulated. The need for patient and provider
education and awareness is clearly emphasized in these
guidelines. In actual practice, however, changes often occur
without the beneﬁt of all relevant parties being involved in
the decision making process. Pharmacists, providers, and
patients are intricately linked in this important area, but
often overlook the importance of two-way communication
and followup when formulation changes are contemplated
or actually undertaken. As such, the guidelines, although
not new, are still relevant for safety but have not been
incorporated into routine practice.
3. Summary
The best available evidence suggests that there are conﬂicting
results as to whether a change from brand name product to
generic equivalent will result in similar levels and outcomes.
The inability to attain similar trough levels in a signiﬁcant
percentageofpatientsaftera1:1switchisaconcern,butthis
shortcoming can be easily corrected by ongoing therapeutic
drug monitoring to ensure that the new steady states fall
within an intended targeted range. Although this may oﬀset
some cost savings in the short term, the signiﬁcant risk of
jeopardizing graft function could be avoided.
Cyclosporine is a narrow therapeutic-range drug for
which small variations in exposure may have severe clinical
consequences for transplant patients. In its Guidance for
Industry on bioequivalence, the FDA recommends “that
sponsors consider additional testing and/or controls to
ensure the quality of drug products containing narrow
therapeuticrangedrugs.Theapproachisdesignedtoprovide
increased assurance of interchangeability for drug products
containing speciﬁed narrow therapeutic range drugs.” How-
ever, FDA guidance does not elaborate what “additional
testing and/or controls” could or should be carried out to
assure the interchangeability for drug products [10].
Currently, there is a lack of comparative outcome data
relatingtothepharmacokineticsofthereferenceformulation
Neoral and generic formulations in transplant recipients.
Prospective clinical studies investigating the eﬃcacy and
safety of generic formulations in both de novo and long-
term transplant patients are also awaited. For drugs such as
cyclosporine,whichexhibitcomplexabsorptionpatternsand
for which maintaining therapeutic exposure levels is critical
to patient wellbeing and survival, the transplant physician
must scrutinize the available pharmacokinetic and clinical
data carefully before prescribing new generic formulations.
Until further evidence is available on the transfer of
transplant patients to or between generic formulations
of cyclosporine, any transfer to a diﬀerent cyclosporine
formulation should be undertaken with close supervision.
The best available information to date, however, does not
support the frequently held but unsubstantiated belief thatJournal of Transplantation 5
generic preparations of immunosuppressive drugs are not as
eﬀective as brand names or that conversion from brand to
generic is associated with signiﬁcant danger.
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